These data predict that DHE reactivation of NR4A nuclear receptors provides an alternative strategy to BET inhibitors to target MYC dependencies in AML cells via suppression of the AML-selective SE governing MYC expression. The gene discussed is DNER; the disease is acute myeloid leukemia.